10,855 Shares in Altimmune, Inc. (NASDAQ:ALT) Purchased by 180 Wealth Advisors LLC

180 Wealth Advisors LLC bought a new position in shares of Altimmune, Inc. (NASDAQ:ALT) in the fourth quarter, Holdings Channel.com reports. The institutional investor bought 10,855 shares of the company’s stock, valued at approximately $78,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of ALT. B. Riley Wealth Advisors Inc. lifted its holdings in Altimmune by 12.9% in the third quarter. B. Riley Wealth Advisors Inc. now owns 23,454 shares of the company’s stock valued at $144,000 after acquiring an additional 2,687 shares during the period. Creative Planning lifted its holdings in Altimmune by 20.5% in the third quarter. Creative Planning now owns 18,411 shares of the company’s stock valued at $113,000 after acquiring an additional 3,132 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in Altimmune by 2.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 211,626 shares of the company’s stock valued at $1,299,000 after acquiring an additional 4,772 shares during the period. Larson Financial Group LLC acquired a new position in Altimmune in the third quarter valued at approximately $31,000. Finally, Arizona State Retirement System lifted its holdings in Altimmune by 34.4% in the second quarter. Arizona State Retirement System now owns 19,847 shares of the company’s stock valued at $132,000 after acquiring an additional 5,081 shares during the period. Institutional investors and hedge funds own 78.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on ALT. Stifel Nicolaus started coverage on Altimmune in a report on Wednesday, January 8th. They issued a “buy” rating and a $18.00 price target for the company. UBS Group started coverage on Altimmune in a research report on Tuesday, November 12th. They issued a “buy” rating and a $26.00 price objective for the company. Finally, HC Wainwright restated a “buy” rating and issued a $12.00 price objective on shares of Altimmune in a research report on Thursday, November 14th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $19.71.

Altimmune Stock Performance

Shares of ALT opened at $6.58 on Thursday. Altimmune, Inc. has a one year low of $5.28 and a one year high of $14.84. The stock has a market capitalization of $468.00 million, a price-to-earnings ratio of -4.25 and a beta of 0.22. The stock has a 50 day moving average price of $8.08 and a 200 day moving average price of $7.20.

Altimmune (NASDAQ:ALT) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.03. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The firm had revenue of $0.01 million during the quarter. During the same quarter in the previous year, the firm posted ($0.39) earnings per share. On average, analysts predict that Altimmune, Inc. will post -1.36 earnings per share for the current year.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.